Detalhe da pesquisa
1.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644155
2.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644154
3.
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Lancet
; 390(10114): 2779-2789, 2017 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29096949
4.
Risankizumab: Mechanism of action, clinical and translational science.
Clin Transl Sci
; 17(1): e13706, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266061
5.
Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease.
Clin Ther
; 46(1): 30-39, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37932155
6.
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
J Crohns Colitis
; 18(3): 416-423, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37797293
7.
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
Aliment Pharmacol Ther
; 57(5): 496-508, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36266762
8.
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease.
Adv Ther
; 40(5): 2311-2325, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36917429
9.
Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in Patients with Crohn's Disease and Ulcerative Colitis.
Pharmacoecon Open
; 7(5): 823-840, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296268
10.
Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease.
Blood
; 116(23): 5010-20, 2010 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-20798237
11.
NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines.
Blood
; 114(3): 667-76, 2009 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-19433855
12.
P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease.
Arterioscler Thromb Vasc Biol
; 30(12): 2392-9, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21071696
13.
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
J Crohns Colitis
; 15(12): 2001-2010, 2021 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34077509
14.
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.
Inflamm Bowel Dis
; 26(2): 304-313, 2020 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31644790
15.
Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.
Inflamm Intest Dis
; 2(4): 228-235, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30221150
16.
Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.
J Crohns Colitis
; 12(10): 1170-1179, 2018 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30032288
17.
Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.
Inflamm Bowel Dis
; 24(5): 932-942, 2018 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29668919
18.
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Lancet Gastroenterol Hepatol
; 3(10): 671-680, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30056030
19.
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease.
Intest Res
; 14(2): 152-63, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27175116
20.
Immunopathology of inflammatory bowel disease.
World J Gastroenterol
; 20(1): 6-21, 2014 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24415853